| アブストラクト | In the past twenty years, the consumption of opioid medications has reached significant proportions, leading to a rise in drug misuse and abuse and increased opioid dependence and related fatalities. Thus, the purpose of this study was to determine whether there are pharmacovigilance signals of abuse, misuse, and dependence and their nature for the following prescription opioids: codeine, dihydrocodeine, fentanyl, oxycodone, pentazocine, and tramadol. Both the pharmacovigilance datasets EudraVigilance (EV) and the FDA Adverse Events Reporting System (FAERS) were analyzed to identify and describe possible misuse-/abuse-/dependence-related issues. A descriptive analysis of the selected Adverse Drug Reactions (ADRs) was performed, and pharmacovigilance signal measures (i.e., reporting odds ratio, proportional reporting ratio, information component, and empirical Bayesian geometric mean) were computed for preferred terms (PTs) of abuse, misuse, dependence, and withdrawal, as well as PTs eventually related to them (e.g., aggression). From 2003 to 2018, there was an increase in ADR reports for the selected opioids in both datasets. Overall, 16,506 and 130,293 individual ADRs for the selected opioids were submitted to EV and FAERS, respectively. Compared with other opioids, abuse concerns were mostly recorded in relation to fentanyl and oxycodone, while tramadol and oxycodone were more strongly associated with drug dependence and withdrawal. Benzodiazepines, antidepressants, other opioids, antihistamines, recreational drugs (e.g., cocaine and alcohol), and several new psychoactive substances, including mitragynine and cathinones, were the most commonly reported concomitant drugs. ADRs reports in pharmacovigilance databases confirmed the availability of data on the abuse and dependence of prescription opioids and should be considered a resource for monitoring and preventing such issues. Psychiatrists and clinicians prescribing opioids should be aware of their misuse and dependence liability and effects that may accompany their use, especially together with concomitant drugs. |
|---|
| ジャーナル名 | Pharmaceuticals (Basel, Switzerland) |
|---|
| Pubmed追加日 | 2022/6/25 |
|---|
| 投稿者 | Chiappini, Stefania; Vickers-Smith, Rachel; Guirguis, Amira; Corkery, John M; Martinotti, Giovanni; Harris, Daniel R; Schifano, Fabrizio |
|---|
| 組織名 | Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit,;School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire;AL10 9EU, UK.;Department of Epidemiology, University of Kentucky College of Public Health, 111;Washington Avenue, Lexington, KY 40536, USA.;Department of Pharmacy, Swansea University Medical School, The Grove, Swansea;University, Swansea, Wales SA2 8PP, UK.;Department of Neurosciences, Imaging and Clinical Sciences, Universita degli;Studi G. D'Annunzio, 66100 Chieti-Pescara, Italy.;Institute for Pharmaceutical Outcomes and Policy, University of Kentucky College;of Pharmacy, 289 South Limestone Street, Lexington, KY 40536, USA.;Center for Clinical and Translational Sciences, University of Kentucky, 800 Rose;Street, Lexington, KY 40506, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35745593/ |
|---|
